Serum Institute of India (SII) announced on Friday its acquisition of a 20 per cent stake in IntegriMedical, marking a significant step forward in advancing needle-free injection system technology. IntegriMedical, a pioneering company in the field, has developed a US-patented needle-free Injection System (N-FIS) that promises to revolutionize drug delivery.
The N-FIS utilizes a high-velocity jet stream powered by mechanical force to administer biologics and drugs effectively and consistently. This innovative approach aims to alleviate pain during administration, particularly benefiting needle-phobic patients and providing them with a stress-free experience. Despite not disclosing the financial details of the transaction, SII emphasized the strategic significance of this investment in driving innovation and enhancing patient comfort.
Adar Poonawalla, CEO of Serum Institute of India, expressed optimism about the potential of IntegriMedical’s N-FIS to transform vaccine delivery. “IntegriMedical’s N-FIS represents a significant advancement in drug delivery, and we envision a needle-free solution to deliver vaccines,” said Poonawalla. He emphasized the potential of this technology to make vaccine administration more comfortable for patients and healthcare professionals alike.
IntegriMedical’s N-FIS has already garnered regulatory approvals from key authorities such as CDSCO (Central Drugs Standard Control Organisation), CE (European regulatory approval), MDSAP (Medical Device Single Audit Program, Australia), and is ISO 13485 certified. Furthermore, the technology holds a US patent, underscoring its innovative and proprietary nature.
Sarvesh Mutha, Managing Director of IntegriMedical, hailed the investment as a testament to the potential of their needle-free Injection System technology. He emphasized the importance of SII’s expertise in vaccine manufacturing and global distribution in expanding the reach of their innovative solution. Mutha expressed confidence that this collaboration would enable IntegriMedical to make their technology more widely accessible to patients worldwide.
The N-FIS technology is set to be introduced in the Indian private market, offering patients and healthcare providers an alternative to traditional needle-based injections. Its advantages include the elimination of needle-phobia, alleviation of pain during administration, convenience of use, and prevention of needle-stick injuries and cross-contamination.
The partnership between Serum Institute of India and IntegriMedical reflects a shared commitment to innovation and improving healthcare delivery. As the world continues to seek safer and more patient-friendly medical solutions, investments in technologies like the N-FIS hold the promise of transforming drug delivery and enhancing patient care on a global scale.
